CN104510724A - Pellet composition containing diclofenac sodium and preparation method thereof - Google Patents
Pellet composition containing diclofenac sodium and preparation method thereof Download PDFInfo
- Publication number
- CN104510724A CN104510724A CN201510008608.3A CN201510008608A CN104510724A CN 104510724 A CN104510724 A CN 104510724A CN 201510008608 A CN201510008608 A CN 201510008608A CN 104510724 A CN104510724 A CN 104510724A
- Authority
- CN
- China
- Prior art keywords
- slow
- quality
- content accounts
- pill
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the field of pharmacy, and particularly relates to a pellet composition containing diclofenac sodium and a preparation method thereof. The composition consists of pellets with different release performances, specifically namely enteric pellets with the total weight of 20-35% and sustained-release pellets with the total weight of 80-65%, wherein the enteric pellets are prepared through enteric coating, the sustained-release pellets are prepared through sustained-release coating, and finally capsules are filled with the enteric pellets and the sustained-release pellets in proportion. The preparation can maintain long blood concentration, and thus the medicine taking frequency is reduced, the adaptability of patients is improved, and the toxic and side effects are reduced. Besides, the adopted preparation technology is easy for large-scale production, little in differences among product batches and high in stability.
Description
Technical field
The present invention relates to pharmaceutical field, be specifically related to a kind of capsule containing sodium dichlorophenolate micro-pill pharmaceutical compositions and preparation method thereof.
Background technology
Diclofenac sodium is the non-steroidal anti-inflammatory analgesics of first being succeeded in developing by Gida-Geigr company of Switzerland, and its mechanism of action for suppressing peroxidase activity, thus blocks arachidonic acid conversion prostaglandin.Diclofenac sodium has the multiple dosage forms such as tablet, capsule, bolt clinically, for alleviating the various arthritic arthralgia symptoms such as rheumatoid arthritis, gouty arthritis, rheumatic arthritis; Treat non-arthrogenous various soft tissue rheumatism pain, as injury pain after shoulder pain, tenosynovitis, myalgia and motion etc.; Acute light, moderate pain as after Post operation, wound, after strain, dysmenorrhea, toothache and headache etc. have refrigeration function etc. to the heating of adult and child.They are as antiinflammatory, analgesia and antipyretic between 36 years of clinical practice, and more than 120 countries in the whole world, apply in hundreds of millions of rheumatic and non-rheumatic patient.Compared with numerous anti-inflammatory agents, its efficacy and saferry is all in good level, and is thought important in anti-inflammatory agent by some researcheres and have the product of higher-value.
In the diclofenac sodium slow release product of current domestic listing, be mainly diclofenac sodium extended release capsule and slow releasing tablet, and two release capsule is import entirely, production firm is German Florian Kringe pharmaceutical factory, two release capsule has unique two delivery systems, is treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, lumbago and skelalgia, gouty arthritis, soft tissue rheumatism, wound or postoperatively to swell and ache or the ideal medicament of inflammation etc.Good effect is all had to the inflammation of various acute and chronic and Combination musculature and pain.The realization of its pair of delivery system is discharged rapidly after entering intestinal by enteric coated micropill, thereafter slow-release micro-pill slow releasing medicine, thus the blood drug level maintaining the long period, reduce times for spraying, reduce adverse effect, and in body, Drug-time curve is bimodal morphology.
Non-steroid antiinflammatory drug clinical application amount is large, demand wide, and current Clinical practice non-steroid antiinflammatory drug generally has the shortcomings such as side effect is large, local drug concentration is large, and this product is multiple-unit dosage form, can effectively solve the problem.Domestic at present only have Germany's list marketing of " wearing sweet smell ", and it is on the high side, the difficulty such as cause patient to use financial burden increase, selection face narrow.Therefore, exploitation is a kind of moderate, and patient's compliance better two release dosage form is very urgent.
Summary of the invention
The object of this invention is to provide a kind of good effect, patient's compliance is high, uses more convenient, the capsule of cheap sodium dichlorophenolate micro-pill pharmaceutical compositions.
Another object of the present invention is to provide a kind of diclofenac sodium dual-release to put the preparation method of preparation.
The object of the present invention is achieved like this: a kind of diclofenac sodium dual-release puts pellet composition, and described pair of delivery formulations is made up of enteric coated micropill and slow-release micro-pill, and both content mass ratioes are 1:2, and its component and content mass percent are respectively following table:
It is 75mg that the preferred two release capsule of the present invention comprises active component diclofenac sodium specification.
In the present invention, the filler of ball core takes from one or more in MCC, microcrystalline Cellulose 301, cross-linking sodium carboxymethyl cellulose.
In in the present invention, the binding agent of ball core takes from the one in hydroxypropyl cellulose, polyvidone, hypromellose.
In the present invention, the one in micropowder silica gel, sodium stearyl fumarate taken from by the fluidizer of ball core.
The antitackiness agent of micropill of the present invention selects the one in Pulvis Talci, glyceryl monostearate;
The one in propylene glycol, triethyl citrate, polyethylene glycol 6000 selected by the plasticizer of micropill of the present invention.
The preferred hypromellose titanate esters (HP55) of enteric material of enteric coated micropill of the present invention, methacrylic acid copolymer C type or its aqueous dispersion.
Slow-release micro-pill of the present invention preferred season ammonio methacrylate resin copolymer Type B (RS30D) and A type (RL30D) or season ammonio methacrylate resin copolymer Type B aqueous dispersion (RS100) and season ammonio methacrylate resin copolymer A type aqueous dispersion (RL100), and preferably A type and Type B mixed proportion are 2:1 respectively.
Optimization formula of the present invention is as follows:
Enteric coated micropill and slow-release micro-pill all adopt ball core, and prepare respectively for 1:2 in mass ratio.
Ball core of the present invention adopts wet-layer preparation soft material to merge extrusion spheronization technology, first soft material is prepared in diclofenac sodium, microcrystalline Cellulose, polyvidone, micropowder silica gel, then prepares ball core by the mesh plate of 0.4-0.6mm.
In the present invention, ball core preferable particle size size is about 0.5mm, adopts 24 order-40 eye mesh screen screenings.
Enteric coated micropill of the present invention is prepared by fluidized bed coating equipment, adopts enteric material, plasticizer and antitackiness agent to prepare enteric coating liquid, and the standard of enteric weightening finish is that in acid, 2h does not discharge, and enteric weightening finish can be 4-20%, preferably weightening finish 10% in the present invention.
Enteric coated micropill of the present invention is prepared by fluidized bed coating equipment, and adopt slow-release material, plasticizer and antitackiness agent to prepare sustained release coating liquid, preferably weightening finish is 8%.
Difene dual release capsules of the present invention, makes diclofenac sodium not discharge under one's belt, greatly reduces the zest in Stomach in Patients; Slow release layer adopts the prescription after optimizing, and coating material consumption greatly reduces.The vitro release test of said preparation shows, its release performance stable uniform, between batch, release difference is little.
Of the present invention couple of release capsule preparation technology is simple, and adopt the ball core that low temperature extrusion spheronization mechanism is standby, roundness is high, and drug distribution is even; Adopt fluidized bed coating equipment simultaneously, be easy to amplify, process stabilizing.
Accompanying drawing explanation
Fig. 1 represents the high-efficient liquid phase chromatogram of diclofenac sodium;
Fig. 2 represents continuous three batches of difene dual release capsules stripping curve in pH6.8 medium;
Fig. 3 represents the two Drug-time curve collection of illustrative plates of release capsule in beasle dog body of self-control;
Fig. 4 represents the high-efficient liquid phase chromatogram of beasle dog blank plasma;
Fig. 5 represents the high-efficient liquid phase chromatogram of diclofenac sodium in Dog Plasma.
Detailed description of the invention
Below all the present invention is further described, but be not limited only to content of the present invention.
Embodiment 1
The preparation of ball core: mix after 60 eye mesh screens are crossed in the diclofenac sodium of recipe quantity, microcrystalline Cellulose and micropowder silica gel; poured in high shear granulator by mixed powder and mix, after incorporation time 3min, arranging rotating speed of agitator is 5rpm; cutter rotating speed is 15rpm, adds 3% polyvidone and prepares soft material.Soft material is added extrusion spheronization machine, arrange extrusion temperature 8 DEG C, extruded velocity 40rpm, round as a ball rotating speed 1500rpm, prepares ball core.Gained ball core is placed in 60 DEG C of baking ovens and dries, when water content lower than 3% time, use 24 order to 40 eye mesh screens screening, get median particle size micropill.
The preparation of enteric coated micropill: the enteric material of recipe quantity is mixed with coating solution, uses 60% ethanol preparation, arranges fluid bed inlet temperature 55 DEG C, atomisation pressure 1.8bar, temperature of charge 35 DEG C, intake 11m
3/ h, stops coating when coating weight gain reaches 10%.
The preparation of slow-release micro-pill: by the slow-release material of recipe quantity thin up in proportion, is mixed with sustained release coating liquid (solid content 20%), arranges fluid bed inlet temperature 40 DEG C, atomisation pressure 1.8bar, temperature of charge 25-30 DEG C, intake 11m
3/ h, stops coating when coating weight gain is 8%.
After being mixed with slow-release micro-pill by enteric coated micropill, pour into in No. 2 capsules, capsule 's content is heavily 200mg.
Embodiment 2
The preparation of ball core: mix after 60 eye mesh screens are crossed in the diclofenac sodium of recipe quantity, microcrystalline Cellulose and micropowder silica gel; poured in high shear granulator by mixed powder and mix, after incorporation time 3min, arranging rotating speed of agitator is 5rpm; cutter rotating speed is 15rpm, adds 5% polyvidone and prepares soft material.Soft material is added extrusion spheronization machine, arrange extrusion temperature 8 DEG C, extruded velocity 40rpm, round as a ball rotating speed 1000rpm, prepares ball core.Gained ball core is placed in 60 DEG C of baking ovens and dries, when water content lower than 3% time, use 24 order to 40 eye mesh screens screening, get median particle size micropill.
The preparation of enteric coated micropill: the enteric material of recipe quantity is mixed with coating solution, uses 95% ethanol preparation, arranges fluid bed inlet temperature 35 DEG C, atomisation pressure 1.8bar, temperature of charge 30 DEG C, intake 11m
3/ h, stops coating when coating weight gain reaches 10%.
The preparation of slow-release micro-pill: the slow-release material of recipe quantity 95% ethanol is mixed with sustained release coating liquid, arranges fluid bed inlet temperature 30 DEG C, atomisation pressure 1.8bar, temperature of charge 20-25 DEG C, intake 11m
3/ h, stops coating when coating weight gain is 8%.
After being mixed with slow-release micro-pill by enteric coated micropill, pour into in No. 2 capsules, capsule 's content is heavily 200mg.
Embodiment 3
The preparation of ball core: mix after 80 eye mesh screens are crossed in the diclofenac sodium of recipe quantity, MCC, cross-linking sodium carboxymethyl cellulose and micropowder silica gel; mixed powder is poured in high shear granulator and mixes; after incorporation time 5min; arranging rotating speed of agitator is 5rpm; cutter rotating speed is 25rpm, adds 5% polyvidone and prepares soft material.Soft material is added extrusion spheronization machine, arrange extrusion temperature 8 DEG C, extruded velocity 40rpm, round as a ball rotating speed 1000rpm, prepares ball core.Gained ball core is placed in 60 DEG C of baking ovens and dries, when water content lower than 3% time, use 24 order to 40 eye mesh screens screening, get median particle size micropill.
The preparation of enteric coated micropill: the enteric material of recipe quantity is mixed with coating solution, uses 95% ethanol preparation, arranges fluid bed inlet temperature 35 DEG C, atomisation pressure 1.8bar, temperature of charge 30 DEG C, intake 11m
3/ h, stops coating when coating weight gain reaches 14%.
The preparation of slow-release micro-pill: the slow-release material of recipe quantity 95% ethanol is mixed with sustained release coating liquid, arranges fluid bed inlet temperature 30 DEG C, atomisation pressure 1.8bar, temperature of charge 20-25 DEG C, intake 11m
3/ h, stops coating when coating weight gain is 5%.
After being mixed with slow-release micro-pill by enteric coated micropill, pour into in No. 2 capsules, capsule 's content is heavily 200mg.
Embodiment 4
The preparation of ball core: mix after the diclofenac sodium of recipe quantity, sucrose and sodium stearyl fumarate are crossed 60 eye mesh screens; mixed powder is poured in high shear granulator and mixes; after incorporation time 3min; arranging rotating speed of agitator is 5rpm; cutter rotating speed is 15rpm, adds 6% hyprolose and prepares soft material.Soft material is added extrusion spheronization machine, arrange extrusion temperature 8 DEG C, extruded velocity 35rpm, round as a ball rotating speed 1500rpm, prepares ball core.Gained ball core is placed in 60 DEG C of baking ovens and dries, when water content lower than 3% time, use 24 order to 40 eye mesh screens screening, get median particle size micropill.
The preparation of enteric coated micropill: the enteric material of recipe quantity is mixed with coating solution, uses 60% ethanol preparation, arranges fluid bed inlet temperature 55 DEG C, atomisation pressure 1.8bar, temperature of charge 35 DEG C, intake 11m
3/ h, stops coating when coating weight gain reaches 18%.
The preparation of slow-release micro-pill: by the slow-release material of recipe quantity thin up in proportion, is mixed with sustained release coating liquid (solid content 20%), arranges fluid bed inlet temperature 40 DEG C, atomisation pressure 1.8bar, temperature of charge 25-30 DEG C, intake 11m
3/ h, stops coating when coating weight gain is 6%.
After being mixed with slow-release micro-pill by enteric coated micropill, pour into in No. 2 capsules, capsule 's content is heavily 200mg.
The stability experiment of two release capsule in the embodiment of the present invention 2
Adopt high performance liquid chromatography to carry out quality research to embodiment 2, under temperature 40 DEG C ± 2 DEG C, relative humidity 75% ± 5% condition, carry out 3 months accelerated stability tests, respectively at 0,1, sampling in March, key index is detected.Wherein liquid-phase condition is: chromatographic column filler is C18,4.6 × 100mm, 5 μm; Be mobile phase with methanol-0.01M potassium dihydrogen phosphate (65:35, with phosphoric acid adjust pH to 4.0 ± 0.05), determined wavelength is 282nm, and column temperature is 40 DEG C, and sample size is 10 μ l, and flow velocity is 1ml/min.
Stability test between the embodiment of the present invention 2 batches
According to prescription described in enforcement example 2, continuous seepage 3 batches, 10,000 every batch, every batch is extracted 12, detects the drug release characteristics of three batches of products, and draw stripping curve (Fig. 2) in pH6.8 dissolution medium, result shows, three batch products releases are comparatively stable, and differences between batches are little.
Described in embodiment 2, two release capsule is in beasle dog body absorption situation
With commercially available sweet smell of wearing for reference, research is from grinding the drug release patterns of diclofenac preparation of sodium in beasle dog body.Before experiment, beasle dog fasting 12h, experiment morning day, on an empty stomach administration Dai Fenyi grain or certainly grind capsule one, used 50ml water delivery service.After the tablet has been ingested, respectively at 0.5,0.75,1,1.5,2,2.5,3,3.5,4,5,6,8,10,12h, adopt vacuum test tube to get blood 3ml in beasle dog foreleg vein, centrifugal (3500r/min) 10min, separated plasma, is stored in-20 DEG C of refrigerator and cooled and freezes to be measured.
Blood plasma testing conditions is: chromatographic column: C18,150mm × 4.6mm × 5 μm (5# post); Mobile phase: methanol-4% glacial acetic acid (75:25); Detector: UV, 282nm; Column temperature: 30 DEG C; Flow velocity: 1.0ml/min; Sampling volume: 20 μ l.Accompanying drawing is shown in by the HPLC collection of illustrative plates of blank plasma (Fig. 4) and sampling blood plasma (Fig. 5).
From data, after homemade difene dual release capsules is taken, rapidly by body absorption, the highest blood drug level (Fig. 3) can be reached at about 1.5h and 2.5h.Wear fragrant capsule compare with commercially available, area under the drug-time curve (AUC), Tmax and Cmax there was no significant difference, illustrate from grinding capsule and commercially availablely wearing fragrant uniform quality.
Claims (5)
1. diclofenac sodium dual-release puts a pellet composition, and it is characterized in that described pair of delivery formulations is made up of enteric coated micropill and slow-release micro-pill, both content mass ratioes are 1:2, and its component and content mass percent are respectively:
Enteric coated micropill consists of:
Diclofenac sodium, its content accounts for 30 ~ 40% of enteric coated micropill quality;
Filler, its content accounts for 40 ~ 50% of enteric coated micropill quality;
Binding agent, its content accounts for 1 ~ 4.5% of enteric coated micropill quality;
Fluidizer, its content accounts for 0.5 ~ 1.5% of enteric coated micropill quality;
Enteric material, its content accounts for 5 ~ 15% of enteric coated micropill quality;
Antitackiness agent, its content accounts for 3.5 ~ 6.5% of enteric coated micropill quality;
Plasticizer, its content accounts for 0.5 ~ 1.5% of enteric coated micropill quality;
Slow-release micro-pill consists of:
Diclofenac sodium, its content accounts for 30 ~ 40% of slow-release micro-pill quality;
Filler, its content accounts for 40 ~ 60% of slow-release micro-pill quality;
Binding agent, its content accounts for 2 ~ 8% of slow-release micro-pill quality;
Fluidizer, its content accounts for 0.5 ~ 1.5% of slow-release micro-pill quality;
Slow-release material, its content accounts for 2 ~ 8% of slow-release micro-pill quality;
Antitackiness agent, its content accounts for 0. 5 ~ 5% of slow-release micro-pill quality;
Plasticizer, its content accounts for 0.3 ~ 2% of slow-release micro-pill quality;
Wherein:
Filler be lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose one or more;
Binding agent is the one of water, polyvidone, hypromellose, hyprolose;
Fluidizer is micropowder silica gel, sodium stearyl fumarate, talcous one;
Enteric material be methacrylic acid copolymer A type, methacrylic acid copolymer Type B, methacrylic acid copolymer C type, HP-55 one or more;
Slow-release material is season ammonio methacrylate resin copolymer Type B and A type mixture or their respective aqueous dispersion mixture;
Antitackiness agent is the one in Pulvis Talci, glyceryl monostearate;
Plasticizer is the one in propylene glycol, triethyl citrate, polyethylene glycol 6000.
2. the compositions of sodium dichlorophenolate micro-pill pharmaceutical according to claim 1, wherein slow-release material season ammonio methacrylate resin copolymer Type B with A type mixture quality than being 5:1 ~ 2:1; Season ammonio methacrylate resin copolymer Type B aqueous dispersion with A type aqueous dispersion mixture quality than for 5:1 ~ 2:1.
3. the compositions of sodium dichlorophenolate micro-pill pharmaceutical according to claim 1 or 2, its dosage form is capsule.
4. diclofenac sodium dual-release puts a pellet composition, and it is characterized in that described pair of delivery formulations is made up of enteric coated micropill and slow-release micro-pill, both content mass ratioes are 1:2, and its component and content mass percent are respectively:
Enteric coated micropill consists of:
Diclofenac sodium, its content accounts for 37.5% of enteric coated micropill quality;
Microcrystalline Cellulose, content accounts for 47% of enteric coated micropill quality;
Polyvidone, content accounts for 4.5% of enteric coated micropill quality;
Micropowder silica gel, content accounts for 1.4% of enteric coated micropill quality;
Methacrylic acid copolymer C type, content accounts for 6% of enteric coated micropill quality;
Pulvis Talci, content accounts for 3% of enteric coated micropill quality;
Triethyl citrate, content accounts for 0.6% of enteric coated micropill quality;
Slow-release micro-pill consists of:
Diclofenac sodium, its content accounts for 37.5% of slow-release micro-pill quality;
Microcrystalline Cellulose, content accounts for 48.2% of slow-release micro-pill quality;
Polyvidone, content accounts for 5% of slow-release micro-pill quality;
Micropowder silica gel, content accounts for 1.3% of slow-release micro-pill quality;
Season ammonio methacrylate resin copolymer Type B and season ammonio methacrylate resin copolymer A type mixture, content accounts for 4.5% of slow-release micro-pill quality;
Pulvis Talci, content accounts for 3% of slow-release micro-pill quality;
Triethyl citrate, content accounts for 0.5% of slow-release micro-pill quality.
5. the preparation method of according to claim 1 pair of releasing micropills compositions, carry out according to the following steps:
(1) micropill preparation: according to a conventional method, component described in claim 1 is got the raw materials ready in proportion, mixed except coating material, prepares fine pellet core;
(2) coating of pellets: fine pellet core prepared by step (1) is put into fluid bed, selects enteric material and slow-release material, adopts fluidized bed coating equipment independently coating;
Enteric coated micropill technological parameter: inlet temperature 35 DEG C, atomisation pressure 1.8bar, temperature of charge 30 DEG C, intake 11m
3/ h, when coating weight gain is 10%, stops coating;
Slow-release micro-pill technological parameter: inlet temperature 30 DEG C, atomisation pressure 1.8bar, temperature of charge 20 ~ 25 DEG C, intake 11m
3/ h, when sustained release coating weightening finish is 8%, stops coating;
(3) mixed: the enteric coated micropill prepare step (2) and slow-release micro-pill, the ratio mixing of 1:2 in mass ratio, with the mixed 8 ~ 10min of three-dimensional mixer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510008608.3A CN104510724A (en) | 2015-01-08 | 2015-01-08 | Pellet composition containing diclofenac sodium and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510008608.3A CN104510724A (en) | 2015-01-08 | 2015-01-08 | Pellet composition containing diclofenac sodium and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104510724A true CN104510724A (en) | 2015-04-15 |
Family
ID=52786963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510008608.3A Pending CN104510724A (en) | 2015-01-08 | 2015-01-08 | Pellet composition containing diclofenac sodium and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104510724A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308127A (en) * | 2016-12-27 | 2017-11-03 | 辅仁药业集团熙德隆肿瘤药品有限公司 | C14H10Cl2NNaO2 multi-unit sustained-release pellet tablet |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980170A (en) * | 1988-06-30 | 1990-12-25 | Klinge Pharma Gmbh | Pharmaceutical formulation as well as a process for its preparation |
| CN101804030A (en) * | 2009-02-12 | 2010-08-18 | 杭州赛利药物研究所有限公司 | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof |
| CN102188388A (en) * | 2010-03-12 | 2011-09-21 | 南京易亨制药有限公司 | Diclofenac sodium sustained-release pellet preparation and preparation method thereof |
| CN103142558A (en) * | 2013-03-25 | 2013-06-12 | 深圳国源国药有限公司 | Diclofenac sodium dual-release enteric-coated preparation, as well as preparation method and control method thereof |
-
2015
- 2015-01-08 CN CN201510008608.3A patent/CN104510724A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980170A (en) * | 1988-06-30 | 1990-12-25 | Klinge Pharma Gmbh | Pharmaceutical formulation as well as a process for its preparation |
| CN101804030A (en) * | 2009-02-12 | 2010-08-18 | 杭州赛利药物研究所有限公司 | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof |
| CN102188388A (en) * | 2010-03-12 | 2011-09-21 | 南京易亨制药有限公司 | Diclofenac sodium sustained-release pellet preparation and preparation method thereof |
| CN103142558A (en) * | 2013-03-25 | 2013-06-12 | 深圳国源国药有限公司 | Diclofenac sodium dual-release enteric-coated preparation, as well as preparation method and control method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308127A (en) * | 2016-12-27 | 2017-11-03 | 辅仁药业集团熙德隆肿瘤药品有限公司 | C14H10Cl2NNaO2 multi-unit sustained-release pellet tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104146976B (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| US20190254976A1 (en) | Medicament-containing hollow particle | |
| CN103181914A (en) | Memantine hydrochloride sustained-release capsule and preparation method thereof | |
| CN110037994A (en) | A kind of brufen quick-release and slow-release double-layer tablets and preparation method thereof | |
| CN103784396B (en) | Ibuprofen oral micropill xerogel and preparation method thereof | |
| CN112587495A (en) | Aspirin and clopidogrel hydrogen sulfate compound preparation and preparation method thereof | |
| CN104814923B (en) | A kind of tamsulosin hydrochloride sustained release preparation and preparation method thereof and its application | |
| JP6009199B2 (en) | Preparation method of the preparation | |
| CN103610658A (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| CN103520169A (en) | Mirtazapine tablet and preparation method thereof | |
| CN107308127A (en) | C14H10Cl2NNaO2 multi-unit sustained-release pellet tablet | |
| CN104510724A (en) | Pellet composition containing diclofenac sodium and preparation method thereof | |
| CN107412198A (en) | Duloxetine hydrochloride enteric slow release granule and preparation method thereof | |
| CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
| CN102973533A (en) | Preparation method of famotidine gastric-floating-type pellet tablets | |
| CN106806353B (en) | Iguratimod sustained-release capsule and preparation method thereof | |
| CN105769773A (en) | Loxoprofen sodium sustained-release pellet | |
| CN106983734B (en) | A kind of ibuprofen sustained release capsules and preparation method thereof | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN114302712B (en) | Acipimox multi-unit sustained-release pellet tablet and preparation method thereof | |
| CN103432149B (en) | A kind of compound capsule containing ilaprazole composition of sodium and preparation method thereof | |
| CN102499929B (en) | 42-(Dimethylphosphinate)rapamycin solid composition and coating method thereof | |
| CN102600108A (en) | Flurbiprofen sustained release capsules and preparation method thereof | |
| CN101642433B (en) | Nimesulide liposome solid preparation and preparation method of drug composite thereof | |
| CN108938587A (en) | A kind of Sustained Release Tablets of Diclofenac Sodium And Its and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150415 |